Document Detail

New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation.
MedLine Citation:
PMID:  17627564     Owner:  NLM     Status:  MEDLINE    
Atrial fibrillation (AF) is associated with a 6 fold increased risk for ischemic stroke. Observational studies suggest that one in four to five strokes is due to AF. Depending on the risk profile of an individual patient, the yearly risk for ischemic stroke is between 2% and 14%. AF is accompanied by an increased propensity for atrial clot formation due to a combination of decreased atrial blood flow, increased activity of the platelet/plasmatic coagulation system and prothrombotic changes at the atrial endocardium. This review summarizes the current guidelines for thromboembolic prevention in patients with AF. In many cases, continuous oral anticoagulation therapy (OAT) with vitamin K antagonists (VitKAs) is indicated if AF is accompanied by more than one additional risk factor for thromboembolic complications. However, therapeutic range of VitKAs (Phenprocoumon, Warfarin, and others), the most commonly used oral anticoagulants, is narrow and their use requires regular anticoagulation monitoring. Possibly due to these limitations, about one third of eligible patients are not treated with VitKAs. Furthermore, in many treated patients OAT is not well controlled. Thus, in clinical practice anticoagulation therapy in AF is suboptimal. Therefore, new and more convenient pharmacologic approaches to prevent thromboembolism with i.e. direct thrombin inhibitors (DTI), synthetic polysaccharides (factor Xa Inhibitors), and others are discussed, and their possible future role in the treatment of AF is evaluated.
Matthias Hammwöhner; Alessandra D'Alessandro; Oliver Wolfram; Andreas Goette
Related Documents :
7930124 - The incidence of pressure sores within a national health service trust hospital during ...
17923414 - Interleukin-2 serum levels variations in recent onset atrial fibrillation are related w...
11767994 - Electrophysiological characteristics and radiofrequency ablation of focal atrial tachyc...
7640824 - Out-of-hours radiographs: the effect of resident registrar cover.
7921094 - Physiologic management of diabetic ketoacidemia. a 5-year prospective pediatric experie...
22979914 - Cu/zn-superoxide dismutase, paraoxonase and arylesterase activities and malondialdehyde...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  5     ISSN:  1570-1611     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-13     Completed Date:  2007-08-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  211-9     Citation Subset:  IM    
University Hospital Magdeburg, Division of Cardiology, Magdeburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / adverse effects,  therapeutic use*
Atrial Fibrillation / complications,  drug therapy*,  metabolism
Factor X / antagonists & inhibitors,  metabolism
Hemorrhage / chemically induced
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Stroke / etiology,  prevention & control*
Thrombin / antagonists & inhibitors,  metabolism
Thromboembolism / complications,  etiology,  prevention & control*
Vitamin K / antagonists & inhibitors,  metabolism
Reg. No./Substance:
0/Anticoagulants; 0/Platelet Aggregation Inhibitors; 12001-79-5/Vitamin K; 9001-29-0/Factor X; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Angiogenic growth factors in the treatment of peripheral arterial disease.
Next Document:  Is there a true beneficial effect of statin therapy in the acute phase of unstable angina or myocard...